167 related articles for article (PubMed ID: 22072492)
1. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome.
Dimicoli S; Jabbour E; Borthakur G; Kadia T; Estrov Z; Yang H; Kelly M; Pierce S; Kantarjian H; Garcia-Manero G
Am J Hematol; 2012 Jan; 87(1):127-9. PubMed ID: 22072492
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Giles F; Fischer T; Cortes J; Garcia-Manero G; Beck J; Ravandi F; Masson E; Rae P; Laird G; Sharma S; Kantarjian H; Dugan M; Albitar M; Bhalla K
Clin Cancer Res; 2006 Aug; 12(15):4628-35. PubMed ID: 16899611
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial).
Bug G; Burchert A; Wagner EM; Kröger N; Berg T; Güller S; Metzelder SK; Wolf A; Hünecke S; Bader P; Schetelig J; Serve H; Ottmann OG
Leukemia; 2017 Nov; 31(11):2523-2525. PubMed ID: 28751769
[No Abstract] [Full Text] [Related]
4. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
DeAngelo DJ; Spencer A; Bhalla KN; Prince HM; Fischer T; Kindler T; Giles FJ; Scott JW; Parker K; Liu A; Woo M; Atadja P; Mishra KK; Ottmann OG
Leukemia; 2013 Aug; 27(8):1628-36. PubMed ID: 23385375
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients.
Platzbecker U; Al-Ali HK; Gattermann N; Haase D; Janzen V; Krauter J; Götze K; Schlenk R; Nolte F; Letsch A; Ottmann OG; Kündgen A; Lübbert M; Germing U; Wermke M; Reinhard H; Weiss C; Lieder K; Ehninger G; Leismann O; Giagounidis A
Leukemia; 2014 Mar; 28(3):696-8. PubMed ID: 24186004
[No Abstract] [Full Text] [Related]
6. Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Kobayashi Y; Munakata W; Ogura M; Uchida T; Taniwaki M; Kobayashi T; Shimada F; Yonemura M; Matsuoka F; Tajima T; Yakushijin K; Minami H
Int J Hematol; 2018 Jan; 107(1):83-91. PubMed ID: 28905323
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Garcia-Manero G; Yang H; Bueso-Ramos C; Ferrajoli A; Cortes J; Wierda WG; Faderl S; Koller C; Morris G; Rosner G; Loboda A; Fantin VR; Randolph SS; Hardwick JS; Reilly JF; Chen C; Ricker JL; Secrist JP; Richon VM; Frankel SR; Kantarjian HM
Blood; 2008 Feb; 111(3):1060-6. PubMed ID: 17962510
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
Catalano MG; Pugliese M; Gargantini E; Grange C; Bussolati B; Asioli S; Bosco O; Poli R; Compagnone A; Bandino A; Mainini F; Fortunati N; Boccuzzi G
Int J Cancer; 2012 Feb; 130(3):694-704. PubMed ID: 21400508
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer.
de Marinis F; Atmaca A; Tiseo M; Giuffreda L; Rossi A; Gebbia V; D'Antonio C; Dal Zotto L; Al-Batran SE; Marsoni S; Wolf M
J Thorac Oncol; 2013 Aug; 8(8):1091-4. PubMed ID: 23857399
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.
Ibrahim N; Buchbinder EI; Granter SR; Rodig SJ; Giobbie-Hurder A; Becerra C; Tsiaras A; Gjini E; Fisher DE; Hodi FS
Cancer Med; 2016 Nov; 5(11):3041-3050. PubMed ID: 27748045
[TBL] [Abstract][Full Text] [Related]
11. The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors.
Cassier PA; Floquet A; Penel N; Derbel O; Bui N'guyen B; Guastalla JP; Pissaloux D; Treilleux I; Saba CE; Blay JY; Ray-Coquard I
Ann Oncol; 2014 May; 25(5):1074-5. PubMed ID: 24651409
[No Abstract] [Full Text] [Related]
12. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer.
Rathkopf DE; Picus J; Hussain A; Ellard S; Chi KN; Nydam T; Allen-Freda E; Mishra KK; Porro MG; Scher HI; Wilding G
Cancer Chemother Pharmacol; 2013 Sep; 72(3):537-44. PubMed ID: 23820963
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity.
Warlick ED; Cao Q; Miller J
Leukemia; 2013 Aug; 27(8):1789-91. PubMed ID: 23446311
[No Abstract] [Full Text] [Related]
14. A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors.
Sharma S; Beck J; Mita M; Paul S; Woo MM; Squier M; Gadbaw B; Prince HM
Invest New Drugs; 2013 Aug; 31(4):974-85. PubMed ID: 23377661
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
Rathkopf D; Wong BY; Ross RW; Anand A; Tanaka E; Woo MM; Hu J; Dzik-Jurasz A; Yang W; Scher HI
Cancer Chemother Pharmacol; 2010 May; 66(1):181-9. PubMed ID: 20217089
[TBL] [Abstract][Full Text] [Related]
16. Panobinostat for the treatment of acute myelogenous leukemia.
Morabito F; Voso MT; Hohaus S; Gentile M; Vigna E; Recchia AG; Iovino L; Benedetti E; Lo-Coco F; Galimberti S
Expert Opin Investig Drugs; 2016 Sep; 25(9):1117-31. PubMed ID: 27485472
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).
Mascarenhas J; Lu M; Li T; Petersen B; Hochman T; Najfeld V; Goldberg JD; Hoffman R
Br J Haematol; 2013 Apr; 161(1):68-75. PubMed ID: 23330839
[TBL] [Abstract][Full Text] [Related]
18. Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation.
Iancu-Rubin C; Gajzer D; Mosoyan G; Feller F; Mascarenhas J; Hoffman R
Exp Hematol; 2012 Jul; 40(7):564-74. PubMed ID: 22381681
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
Ellis L; Pan Y; Smyth GK; George DJ; McCormack C; Williams-Truax R; Mita M; Beck J; Burris H; Ryan G; Atadja P; Butterfoss D; Dugan M; Culver K; Johnstone RW; Prince HM
Clin Cancer Res; 2008 Jul; 14(14):4500-10. PubMed ID: 18628465
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
